Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04604431 · ClinicalTrials.gov registry record · NA

Intervention to Reduce Early (Peanut) Allergy in Children

A NA study of Food Allergy in Infants and Food Allergy Peanut, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

Active
Registry status
NA
Development phase
30
Enrollment target
20
Study locations

NCT04604431 is a NA study of Food Allergy in Infants and Food Allergy Peanut that is active but no longer recruiting, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 30 participants, below the 4,974-participant average among 5 other Food Allergy in Infants trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04604431, a NA study of Food Allergy in Infants and Food Allergy Peanut, is active but no longer recruiting, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
20
Study locations

Study Summary

iREACH is a five-year NIH funded study aimed at assessing and improving pediatric clinician adherence to the 2017 NIAID Prevention of Peanut Allergy (PPA) Guidelines. iREACH has been developed as an electronic health record (EHR) integrated Clinical Decision Support (CDS) tool together with educational modules on the PPA guidelines to assist clinicians in implementing the 2017 NIAID PPA Guidelines. A practice-based, two-arm, cluster-randomized clinical trial will evaluate the effectiveness of iREACH in increasing pediatric clinician adherence to the PPA Guidelines and explore the end-goal of reducing peanut allergy incidence by age 2.5 years in the intervention vs control group. This study has the potential to: 1) provide evidence regarding the effectiveness of iREACH in promoting clinical processes and outcomes related to the PPA Guidelines, 2) provide important insight about practice-based implementation of PPA Guidelines by pediatric clinicians, allergists and caregivers, and 3) facilitate rapid, widespread implementation of PPA Guidelines and reduce peanut allergy incidence across the US.

Interventions

  • OTHER iREACH CDS Tool

Study Locations (20)

Illinois

  • Pediatric Associates of Arlington Heights, SC-PEDIATRUST - Arlington Heights
  • OSF Medical Group Pediatrics Bloomington - Bloomington
  • Child and Adolescent Health Associates - Chicago
  • Northwestern Children's Practice - Chicago
  • Streeterville Pediatrics - Chicago
  • Erie Family Health Centers - Erie Teen and Young Adult Health Center - Chicago
  • Erie Family Health Centers - West Town - Chicago
  • Erie Family Health Centers - Helping Hands - Foster - Chicago
  • Lurie Children's Primary Care Town & Country Pediatrics - Chicago
  • Near North Health Services Corporation - Chicago
  • Children's Health Associates - Chicago
  • Lakeview Pediatrics - Chicago
  • OSF Medical Group Pediatrics Danville - Danville
  • Erie Family Health Centers - Evanston - Evanston
  • Lurie Children's Primary Care Chicago Area Pediatrics - Evanston
  • OSF Medical Group Pediatrics Godfrey - Godfrey
  • Pediatric Partners, SC-PEDIATRUST - Highland Park
  • Bedrose Pediatrics - Hoffman Estates
  • Lake Shore Pediatrics, SC-PEDIATRUST - Libertyville
  • OSF Medical Group (MG)-Morton Pediatrics - Morton

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2020-11-04
Est. Completion 2025-12-31
Phase NA

What the Registry Record Tells You About NCT04604431

The ClinicalTrials.gov registry entry for NCT04604431 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,974-participant average among 5 other Food Allergy in Infants trials with a reported enrollment target (99% lower). The listed sponsor is Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Food Allergy in Infants appearing as the primary indexed condition, and to 1 intervention - of which iREACH CDS Tool is the first listed.

NCT04604431 reports 20 study locations spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT04604431 about?

NCT04604431 is a clinical study titled "Intervention to Reduce Early (Peanut) Allergy in Children". iREACH is a five-year NIH funded study aimed at assessing and improving pediatric clinician adherence to the 2017 NIAID Prevention of Peanut Allergy (PPA) Guidelines. iREACH has been developed as an electronic health record (EHR) integrated Clinical Decision Support (CDS) tool together with educati...

What is the current status of trial NCT04604431?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2020-11-04. Estimated completion is 2025-12-31.

What conditions does trial NCT04604431 study?

This clinical trial studies the following conditions: Food Allergy in Infants, Food Allergy Peanut.

What interventions are being tested in trial NCT04604431?

The interventions under investigation include: iREACH CDS Tool (OTHER).

Who is sponsoring clinical trial NCT04604431?

This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04604431 being conducted?

This trial has 20 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Food Allergy in Infants

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.